Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
43.40B
Market cap43.40B
Price-Earnings ratio
137.16
Price-Earnings ratio137.16
Dividend yield
Dividend yield
Average volume
1.08M
Average volume1.08M
High today
$330.30
High today$330.30
Low today
$324.44
Low today$324.44
Open price
$327.49
Open price$327.49
Volume
1.02M
Volume1.02M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

With a market cap of 43.4B, Alnylam Pharmaceuticals(ALNY) trades at $327.30. The stock has a price-to-earnings ratio of 137.16.

As of 2026-04-09, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $324.44 and $330.30. The current price stands at $327.30, placing the stock +0.9% above today's low and -0.9% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 1.02M, compared to an average daily volume of 1.08M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

ALNY News

TipRanks 1d
Top Alnylam Executive Makes Eye-Catching Move With Company Stock

New insider activity at Alnylam Pharma ( (ALNY) ) has taken place on April 7, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, shar...

Nasdaq 2d
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?

Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 19...

Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
Simply Wall St 6d
A Look At Alnylam Pharmaceuticals Valuation After New Cardiovascular Data And Partnerships At ACC.26

Alnylam Pharmaceuticals (ALNY) has drawn fresh attention after presenting extensive cardiovascular data at ACC.26. The company highlighted vutrisiran in amyloid...

A Look At Alnylam Pharmaceuticals Valuation After New Cardiovascular Data And Partnerships At ACC.26

Analyst ratings

71%

of 28 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.